| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 08/01/2002 | US20020102619 Heparanase specific molecular probes and their use in research and medical applications |
| 08/01/2002 | US20020102585 Prostate growth-associated membrane proteins |
| 08/01/2002 | US20020102569 Nucleotide sequences for use in the detection, classificataions, treatment and evaluation of cancer therapies |
| 08/01/2002 | US20020102566 Identification of neural defects associated with the nucleosomal assembly protein 112 gene |
| 08/01/2002 | US20020102540 Functional dna clone for hepatitis c virus (hcv) and uses thereof |
| 08/01/2002 | US20020102535 Nucleic acid molecules and polypeptides for immune modulation |
| 08/01/2002 | US20020102298 Temperature-sensitive liposomal formulation |
| 08/01/2002 | US20020102296 Small particle liposome aerosols for delivery of anti-cancer drugs |
| 08/01/2002 | US20020102294 Aerosols comprising nanoparticle drugs |
| 08/01/2002 | US20020102265 For diagnosis and imaging of cancer and tumor tissues |
| 08/01/2002 | US20020102263 Diagnosis and treatment of malignant neoplasms |
| 08/01/2002 | US20020102254 For diagnostic and therapeutic uses in cancer |
| 08/01/2002 | US20020102247 For therapy of hyperproliferative disorders |
| 08/01/2002 | US20020100854 Furnace mount and method of installation |
| 08/01/2002 | DE10103244A1 Übergangsmetallkomplexe mit Protonenschwämmen als Liganden Transition metal complexes with proton sponges as ligands |
| 08/01/2002 | DE10101890A1 HPV-spezifische Peptide, die die Bindung von HPV an die Wirtszelle blockieren HPV specific peptides that block the binding of HPV to the host cell |
| 08/01/2002 | DE10101307A1 Fumarsäurederivate als NF-kappaB-Inhibitor Fumaric acid derivatives as NF-kappaB inhibitor |
| 08/01/2002 | CA2735478A1 Malonyl-coa decarboxylase inhibitors useful as metabolic modulators |
| 08/01/2002 | CA2735267A1 Malonyl-coa decarboxylase inhibitors useful as metabolic modulators |
| 08/01/2002 | CA2599884A1 Combinations of drugs for the treatment of neoplastic disorders |
| 08/01/2002 | CA2436139A1 Methods of inducing organ transplant tolerance and correcting hemoglobinopathies |
| 08/01/2002 | CA2435949A1 Biological organism for preparing pharmaceutical compositions for treating mammals |
| 08/01/2002 | CA2435888A1 Method of preparing biological materials and preparation produced using same |
| 08/01/2002 | CA2435829A1 Trisubstituted carbocyclic cyclophilin binding compounds and their use |
| 08/01/2002 | CA2435776A1 Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines |
| 08/01/2002 | CA2435775A1 2h-1-benzopyran derivatives, processes for their preparation and pharmaceutical compositions thereof |
| 08/01/2002 | CA2435773A1 Transition metal complexes with proton sponges as ligands |
| 08/01/2002 | CA2435672A1 Polypeptides capable of binding to cd64 and comprising one or more heterologous t cell epitopes, and their uses |
| 08/01/2002 | CA2435653A1 Anti-cancer 2,3-dihydro-1h-pyrrolo[3,2-f]quinoline complexes of cobalt and chromium |
| 08/01/2002 | CA2435647A1 Urea derivatives, method for preparing same, use thereof as medicines, pharmaceutical compositions and use |
| 08/01/2002 | CA2435633A1 Antiangiogenic compounds and an assay for inhibitors of cell invasion |
| 08/01/2002 | CA2435510A1 Methods for screening for substances which inhibit fp prostanoid receptor interaction with a compound having pgf2.alpha.alphaactivity and methods of treating cancer |
| 08/01/2002 | CA2435409A1 Novel cannabimimetic ligands |
| 08/01/2002 | CA2435124A1 Formulation of boronic acid compounds |
| 08/01/2002 | CA2435047A1 Constitutively desensitized g protein-coupled receptors |
| 08/01/2002 | CA2434584A1 Pharmaceutical compositions, dosage forms and methods for oral administration of epothilones |
| 08/01/2002 | CA2434320A1 Chemokines as adjuvants of immune response |
| 08/01/2002 | CA2434085A1 Cyclin dependent kinase inhibiting purine derivatives |
| 08/01/2002 | CA2433681A1 Sulfatases and methods of use thereof |
| 08/01/2002 | CA2433227A1 Specific human antibodies for selective cancer therapy |
| 08/01/2002 | CA2432991A1 Genes overexpressed in prostate disorders as diagnostic and therapeutic targets |
| 08/01/2002 | CA2432276A1 Regulation of cell growth by muc1 |
| 08/01/2002 | CA2432134A1 Adenylate cyclases |
| 08/01/2002 | CA2431904A1 (halo-benzo carbonyl)heterocyclo fused phenyl p38 kinase inhibiting agents |
| 08/01/2002 | CA2431493A1 Aminoacyl trna synthetases |
| 08/01/2002 | CA2431313A1 Methods of diagnosing colorectal cancer and/or breast cancer, compositions, and methods of screening for colorectal cancer and/or breast cancer modulators |
| 08/01/2002 | CA2430743A1 Isolated human phospholipase proteins, nucleic acid molecules encoding human phospholipase proteins, and uses thereof |
| 08/01/2002 | CA2429034A1 Methods for inhibiting proliferation of astrocytes and astrocytic tumor cells and uses thereof |
| 08/01/2002 | CA2428425A1 Method of treating hematologic tumors and cancers |
| 08/01/2002 | CA2427647A1 Nucleic acid modification enzymes |
| 08/01/2002 | CA2427061A1 Methods and compositions for the identification and treatment of neurodegenerative disorders |
| 08/01/2002 | CA2424402A1 Antimicrobial quinolone derivatives and use of the same to treat bacterial infections |
| 07/31/2002 | EP1227152A1 Bacterial strain and genome of bifidobacterium |
| 07/31/2002 | EP1227105A1 Ghsr ligand polypeptides and dnas thereof |
| 07/31/2002 | EP1227098A1 Triazolopurine derivatives, drug compositions containing the same and adenosine a3 receptor affinitive agents |
| 07/31/2002 | EP1227097A1 Ucs1025 derivatives |
| 07/31/2002 | EP1227093A2 Beta-lactams useful for preparation of taxanes having furyl or thienyl substituted side-chain |
| 07/31/2002 | EP1227090A1 Amine derivatives |
| 07/31/2002 | EP1227086A1 1-substituted phenyl-1-(1h-imidazol-4-yl) alcohols, process for producing the same and use thereof |
| 07/31/2002 | EP1227085A1 Process for producing optically active naphthalene derivative and optical resolver therefor |
| 07/31/2002 | EP1227083A1 3-AMINOPIPERIDINE DERIVATIVES AS INTEGRIN $g(a)v$g(b)3 ANTAGONISTS |
| 07/31/2002 | EP1226824A1 Use of thalidomide for the treatment of hepatocellular carcinoma |
| 07/31/2002 | EP1226823A2 Method of treating certain cancers using an estrogen agonist/antagonist |
| 07/31/2002 | EP1226822A2 Promoter for production of nitric oxide or nitric oxide synthase, and cosmetic or pharmaceutical composition comprising the same |
| 07/31/2002 | EP1226441A1 Protein tyrosine kinase receptor polynucleotides, polypeptides, and antibodies |
| 07/31/2002 | EP1226279A1 Modulation of neuroendocrine differentiation by protein 25.1 |
| 07/31/2002 | EP1226263A1 Invasive bacterial vectors for expressing alphavirus replicons |
| 07/31/2002 | EP1226252A2 DOUBLE-STRANDED RNA RECEPTOR (dsRNA-R) AND METHODS RELATING THERETO |
| 07/31/2002 | EP1226251A2 CpG RECEPTOR (CpG-R) AND METHODS RELATING THERETO |
| 07/31/2002 | EP1226248A1 Cloning, expression and characterisation of a gene expressed in tumour cells and involved in the regulation of the immune response |
| 07/31/2002 | EP1226247A1 Human gpr27-like g-protein coupled receptor polypeptide and polynucleotide sequences |
| 07/31/2002 | EP1226246A1 Polypeptides with expanded primary signalling motifs |
| 07/31/2002 | EP1226245A2 Hybrid adaptor receptors |
| 07/31/2002 | EP1226244A2 Polypeptides with non-natural primary signalling motifs |
| 07/31/2002 | EP1226243A2 Nucleic acid molecules derived from rat brain and programmed cell death models |
| 07/31/2002 | EP1226239A1 Methods of producing differentiated progenitor cells and lineage-defective embryonic stem cells |
| 07/31/2002 | EP1226237A2 Method of identifying inhibitors of cdc25 |
| 07/31/2002 | EP1226235A2 Cell constructs that are suitable for immunotherapy, the production and the use thereof |
| 07/31/2002 | EP1226231A1 19 human secreted proteins |
| 07/31/2002 | EP1226178A1 Recombinant fusion molecules |
| 07/31/2002 | EP1226177A2 Anti-prostate stem cell antigen (psca) antibody compositions and methods of use |
| 07/31/2002 | EP1226170A2 Human proteins and polynucleotides encoding the same |
| 07/31/2002 | EP1226168A1 Ligand activated transcriptional regulator proteins |
| 07/31/2002 | EP1226166A1 Immuno-interactive fragments of the alpha c subunit of inhibin |
| 07/31/2002 | EP1226161A2 Apo-2 receptor antibodies |
| 07/31/2002 | EP1226160A2 Novel antiarrhythmic peptides |
| 07/31/2002 | EP1226159A1 Substituted dipeptides having nos inhibiting activity |
| 07/31/2002 | EP1226155A2 18-nor-steroids as selectively active estrogens |
| 07/31/2002 | EP1226154A1 Estradiol conjugates and uses thereof |
| 07/31/2002 | EP1226151A2 Gene expression directed by a super-psa promoter |
| 07/31/2002 | EP1226150A1 Tadg-15: an extracellular serine protease overexpressed in carcinomas |
| 07/31/2002 | EP1226141A1 Heterocyclic substituted pyrazolones |
| 07/31/2002 | EP1226137A1 Phenyl- and pyridyl-tetrahydro-pyridines having tnf inhibiting activity |
| 07/31/2002 | EP1226136A2 Tyrosine kinase inhibitors |
| 07/31/2002 | EP1226129A1 Methods and compositions utilizing quinazolinones |
| 07/31/2002 | EP1226128A1 New pyrimidine-2,4,6-trione derivatives, processes for their production and pharmaceutical agents containing these compounds |
| 07/31/2002 | EP1226126A1 Pyrimidine derivatives |
| 07/31/2002 | EP1226125A2 Method for producing therapeutic agents for ulcers |
| 07/31/2002 | EP1226124A1 Heterocyclically substituted benzoylguanidine, method for the production thereof, the use thereof as a medicament or means of diagnosis and a medicament containing the same |
| 07/31/2002 | EP1226119A2 Tyrosine kinase inhibitors |